Why Talking About Mounjaro in India Still Takes Courage — And Why That Has to Change

A comedian shared her GLP-1 journey publicly. The internet called it brave. It should have been ordinary. Here is why that gap matters more than you think.

The Post That Started a Conversation

Recently, popular Indian stand-up comedian Aishwarya Mohanraj did something that went quietly viral in India's health and wellness circles. She shared her experience with Mounjaro — one of the most effective GLP-1 receptor agonist medications currently available for weight loss and metabolic health — openly, honestly, and on her own terms.

The response was warm. The comments were supportive. People called it refreshing. Several called it brave.

And it was brave. Genuinely. The fact that she spoke about her experience without hedging, without excessive qualification, and without the kind of performative shame that usually accompanies any public admission of using weight loss medication in India — that took something.

But here is the thing that nobody in those supportive comment sections said out loud.

It should not have taken courage. Not in 2026. Not for a medication that is backed by some of the most robust clinical trial data in the history of metabolic medicine. Not for a treatment that is already transforming the health of millions of people globally.

The fact that it did — the fact that publicly discussing a prescribed medication for a serious health condition is still considered an act of bravery in India — tells us something important and uncomfortable about where we actually are with GLP-1 adoption in this country.

And it tells us exactly what the biggest barrier to GLP-1 reaching the Indians who need it most actually is. It is not access. It is not cost. It is not doctor availability.

It is stigma. Deep, culturally embedded, largely unexamined stigma around the idea of losing weight through medication.

The Subtext Nobody Is Naming

When someone calls a public health disclosure an act of courage, they are — often without realising it — confirming that the default expectation is silence.

Courage is required when speaking involves risk. Social risk. Reputational risk. The risk of judgment, of being misunderstood, of being seen differently by the people whose opinions matter to you.

So when we applaud Aishwarya for her courage in speaking about Mounjaro, we are simultaneously acknowledging that the alternative — staying silent — would have been the safer, more socially acceptable choice. We are confirming that in India's current cultural conversation around weight and health, using medication to lose weight is something you are expected to keep private.

The subtext is not subtle once you see it.

Losing weight through medication means you cheated. It means you lacked the discipline to do it the right way. It means you took a shortcut. It means — and this is the most damaging version of the narrative — that your weight loss is somehow less valid, less earned, less deserving of acknowledgement than the person who lost the same amount through diet and exercise alone.

This narrative is not just unkind. It is medically illiterate.

Obesity is not a character flaw. It is a complex, multifactorial chronic disease with genetic, hormonal, environmental, and behavioural components that interact in ways that simple willpower cannot address. The same compassion and clinical seriousness we extend to someone managing Type 2 diabetes with metformin, or hypertension with antihypertensives, or depression with SSRIs — that same framework applies to someone managing obesity with a GLP-1 receptor agonist.

But we do not yet apply it. Not in India. Not consistently. Not without courage being required to say so.

Why This Stigma Is a Public Health Problem

This is not just a matter of social justice or individual dignity — although it is both of those things. The stigma around GLP-1 medication in India is a concrete, measurable barrier to public health impact at scale.

Consider how genuinely new medical categories have always achieved mainstream adoption throughout history. Statins — now among the most widely prescribed medications on earth — spent years being whispered about before they became ordinary. Antidepressants carried enormous stigma before the combination of celebrity disclosure, patient advocacy, and open cultural conversation gradually normalised them. Metformin, the foundational medication for Type 2 diabetes management, achieved its current ubiquity not through advertising alone but through the accumulated weight of millions of people telling other people — this works, it helped me, ask your doctor.

The pattern is consistent across every major pharmaceutical category that has successfully transitioned from specialist prescription to mainstream treatment. Clinical evidence gets you into doctors' offices. Word of mouth gets you into culture. And culture is what determines whether the person who needs a treatment actually seeks it, accepts it, and sustains it.

GLP-1 medications are at a critical inflection point in India. The clinical evidence is overwhelming. Regulatory approvals are in place. A growing number of endocrinologists and metabolic physicians are prescribing them. The infrastructure for mainstream adoption exists or is being built.

But if every person who uses GLP-1 medications in India feels that honest disclosure requires an act of courage, the word of mouth engine that drives mainstream adoption cannot function. The person sitting next to you at work who is struggling with obesity and metabolic disease will never know that their colleague tried Mounjaro and it changed their life — because their colleague decided the social cost of disclosure was too high.

That silence has consequences measured not in social comfort but in health outcomes. In years of life. In diabetes diagnoses that could have been prevented. In cardiovascular events that did not have to happen.

The Courage Tax on Indian GLP-1 Users

There is a concept worth naming here: the courage tax.

Every time a person using a GLP-1 medication in India has to decide whether to disclose their treatment, they pay a courage tax. They have to calculate the social risk. Anticipate the judgment. Prepare the justification. Decide whether the honesty is worth the potential cost to how they are perceived.

This tax falls disproportionately on women, who already navigate a brutal cultural landscape of body commentary and weight judgment in India. It falls on people in conservative professional environments where any admission of health struggle can be read as weakness. It falls on people whose families hold strong views about natural versus medical approaches to health. It falls on anyone who has already been told — explicitly or implicitly — that their weight is a reflection of their character.

The courage tax is exhausting. And it is one of the primary reasons that GLP-1 users in India are significantly more likely to be silent about their treatment than their counterparts in the United States or the United Kingdom, where the cultural conversation — while still imperfect — is considerably more open.

This silence creates a vicious cycle. Because the silence means that the next person who might benefit from GLP-1 medications never gets the casual, honest, peer-level information that would make them comfortable enough to ask their doctor. The stigma perpetuates itself through the absence of normalising conversation.

What Aishwarya's Post Actually Demonstrated

Beyond the personal courage it required, Aishwarya Mohanraj's disclosure demonstrated something important about the potential of open conversation to shift the narrative.

The response was not predominantly negative. It was not dominated by the "cheating" narrative or the easy-way-out judgment that many GLP-1 users in India fear. It was largely supportive, curious, and — critically — full of people asking questions. People who had wondered about GLP-1 medications but had never heard a real, relatable, first-person account from someone whose life and context felt familiar to them.

That is the power of authentic peer disclosure. Not a pharmaceutical advertisement. Not a doctor's clinical explanation. A real person saying — here is what I did, here is what happened, here is what I would tell you.

One post from one person with a public platform created more genuine GLP-1 awareness and destigmatisation than months of clinical content ever could. Imagine what happens when that is not an act of courage but an ordinary conversation.

What Needs to Change — And Who Needs to Change It

The stigma around GLP-1 medication in India will not dissolve on its own. It requires active, deliberate effort from several directions simultaneously.

Health professionals need to normalise the conversation in their own communication — treating GLP-1 prescription with the same clinical matter-of-factness as any other evidence-based intervention, and actively countering the "cheating" narrative when they encounter it in their patients.

Public figures and celebrities — who have disproportionate influence over cultural norms in India — have an opportunity and arguably a responsibility to share their experiences when they choose to use these medications. Not because they owe anyone their medical history, but because their visibility carries a normalising power that ordinary individuals simply do not have.

Media and content platforms need to cover GLP-1 medications with the same seriousness and nuance they apply to other significant medical developments — not as celebrity gossip, not as controversy, but as a legitimate and important development in metabolic medicine.

And most importantly, the people using GLP-1 medications in India — the everyday users, not the celebrities — need to feel that they have the support, the community, and the information to share their experiences without paying the courage tax.

That last part is the hardest. And it is the part that no pharmaceutical company, no doctor, and no media platform can fully deliver. It requires a community. A space where GLP-1 users in India can find each other, share honestly, ask questions without judgment, and gradually build the kind of collective normalisation that makes the next person's disclosure a little less costly.

The Conversation India Needs to Have

India has the second largest diabetic population in the world. Obesity and metabolic disease are rising steeply, particularly in urban populations. The window for intervention — the period where treatment can genuinely reverse rather than merely manage metabolic decline — is finite for hundreds of millions of people.

GLP-1 medications represent a genuine opportunity to bend that curve. Not as a magic solution. Not as a replacement for nutrition, lifestyle, and behavioural change. But as a powerful clinical tool that, used appropriately and supported properly, can give people a real chance at metabolic health who would otherwise struggle to achieve it.

That opportunity is being limited — not by science, not by medicine, not even primarily by cost and access — but by a cultural conversation that still requires courage to participate in.

Aishwarya Mohanraj was brave. She should not have had to be.

The medication is ready. The science is ready. The need is urgent and enormous.

The conversation is the thing that needs to catch up.

How Caddy Is Building That Community

Caddy was built in direct response to the gap between what GLP-1 users in India need and what currently exists to support them.

Not another clinical explainer. Not a pharmaceutical support programme designed primarily to ensure medication adherence. A genuine companion — built around Indian food, Indian bodies, Indian cultural context, and the real lived experience of navigating weight loss and metabolic health in India in 2026.

Part of what Caddy is building is a space where GLP-1 users in India can find each other. Share honestly. Ask the questions they are embarrassed to ask their doctor. Celebrate their progress without justifying it. And gradually, collectively, reduce the courage tax that every Indian GLP-1 user currently pays just to be honest about their own health journey.

Because the most powerful thing that can happen for GLP-1 adoption in India is not a better advertisement. It is the person in your office, your building, your family WhatsApp group saying — yes, I'm on it, yes it's working, yes you can ask me about it.

Casually. Honestly. Without armour.

That is the conversation Caddy is trying to make possible.